 Pliant Therapeutics Incs NASDAQ: PLRX Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis IPF met its primary and secondary endpoints. The data demonstrated that PLN-74809 was well tolerated over a 12-week treatment period and displayed a favorable. 